Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (8567)	1/13/2001 3:10:21 PM
From: bosquedog	Read Replies (1) \| Respond to of 9719

This is part of Lissa Morgenthaler's response to Cramer: "Note to Cramer: I am sick and tired of explaining why this sector isn't going away. Buzz may be gone, but I'm still here and somebody needs to whap you upside the head. Biotech is not the Internet all over again. These companies are finding cures for cancer and weight gain and tooth decay and all the other miseries afflicting 45-year-old former hedgies who sit around typing too much and exercising too little. When your tobacco companies are the footnote to disease they so richly deserve to be, biotech companies will still be cranking out cures."

To: Vector1 who wrote (8567)	1/13/2001 4:07:51 PM
From: rkrw	Respond to of 9719

Great commentary. I'd also argue that the pharmaceutical industries small biotech brethren are in better condition to balance the playing field than ever before. 2000 may have resembled a bubble, but unlike internet companies who bled dry, wiping out shareholder capital at rapid speed, biotechs stockpiled cash by the $billions. So biotechs are sitting in a golden age of genetic knowledge coupled with their strongest financial condition ever. Resources not only to develop deep pipelines but the resources to market and earn for shareholders the vast majority of profits as opposed to the old model of outlicensing long shot drugs for 5% royalties that, for the majority, never came. When assessing biotechs, the question used to be "what partnerships have been signed?" Now the question is what haven't they signed away? Biotechs have smartened up and are retaining the majority of their products. This will create huge excess shareholder value with the success stories. If anything the inherent value in well situated biotechs has gone up dramatically. I see this value going up every day. Incidentally, TSCM stock sits at $2.50 per share, down from a high of $70.